Source: European Parliament
Question for written answer E-000646/2025/rev.1
to the Commission
Rule 144
Loucas Fourlas (PPE)
The availability of critical medicines is a key public health priority in the European Union. Nonetheless, in recent years, the shortage of essential medicines such as antibiotics, painkillers and treatments for chronic diseases has become a serious problem, affecting patient care. At the same time, the EU’s increased dependence on non-EU countries for the production of active ingredients and medicines increases the vulnerability of the supply chain.
In view of the initiatives to strengthen pharmaceutical autonomy:
- 1.How does the Commission intend to reduce the EU’s dependence on non-EU countries for the production of active pharmaceutical ingredients?
- 2.Have any plans been put together to boost the domestic production of medicines and build up strategic stockpiles for times of crisis?
Submitted: 12.2.2025
Last updated: 26 February 2025